When performed in tandem, two molecular biology laboratory tests distinguish, with near certainty, pancreatic lesions that mimic early signs of cancer but are benign.
Anna Berkenblit, a clinical oncologist and drug developer, was named the first-ever chief scientific and medical officer of the Pancreatic Cancer Action Network.
